CLDX FY 2017 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+87.8% YoY

Gross Profit

-$83M-654.7% margin

Operating Income

-$122M-953.7% margin

Net Income

-$93M-730.1% margin

EPS (Diluted)

$-10.86

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$102M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$316M

Total Liabilities

$79M

Stockholders' Equity

$236M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$7M	+87.8%
Gross Profit	-$83M	-$95M	+12.4%
Operating Income	-$122M	-$133M	+8.6%
Net Income	-$93M	-$129M	+27.6%